Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE Trial: 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy in Stage III Colon Cancer
jRCTs031180129Phase 3Completed
- Sponsor
- Yakult Honsha
- Start
- Aug 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, capecitabine, fluorouracil and folinic acid in colon adenocarcinoma and Rectosigmoid Adenocarcinoma (2 arms), sponsored by Yakult Honsha. Primary endpoint: Disease-free survival (IDEA definition). Started Aug 2012; status: completed.
02
Drugs
oxaliplatincapecitabinefluorouracilfolinic acid
03
Conditions
colon adenocarcinomaRectosigmoid Adenocarcinoma
Beyond the preview
Go deeper on jRCTs031180129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180129.